| 3.7 -0.05 (-1.33%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.48  |
1-year : | 5.23 |
| Resists | First : | 3.83 |
Second : | 4.48 |
| Pivot price | 3.32 |
|||
| Supports | First : | 2.92 |
Second : | 2.35 |
| MAs | MA(5) : | 3.59 |
MA(20) : | 3.23 |
| MA(100) : | 2.86 |
MA(250) : | 3.26 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 86.3  |
D(3) : | 85.4 |
| RSI | RSI(14): 67 |
|||
| 52-week | High : | 5.46 | Low : | 2.31 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ANIX ] has closed below upper band by 11.5%. Bollinger Bands are 95.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 22 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.85 - 3.87 | 3.87 - 3.88 |
| Low: | 3.56 - 3.58 | 3.58 - 3.59 |
| Close: | 3.67 - 3.7 | 3.7 - 3.73 |
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Fri, 24 Jul 2026
ANIX|Anixa Biosciences Inc|Price:3.700|Chg%:-0.050 - TradingKey
Fri, 24 Jul 2026
Anixa Biosciences Inc (ANIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Wed, 22 Jul 2026
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance Singapore
Wed, 22 Jul 2026
New Strong Buy Stocks for July 22nd - The Globe and Mail
Tue, 21 Jul 2026
Anixa Biosciences (ANIX) CEO buys 5,000 common shares - Stock Titan
Mon, 20 Jul 2026
Insider Buying: Titterton Lewis H Jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 15.1 (%) |
| Shares Short | 886 (K) |
| Shares Short P.Month | 1,010 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.43 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42 % |
| Return on Equity (ttm) | -72 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -12.76 |
| PEG Ratio | -0.2 |
| Price to Book value | 8.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|